Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

There are enormous differences in benzo[a]pyrene (BaP) acute toxicity tests on , according to previous publications. The explanations of the reasons for this extreme variation are necessary. In this context, the acute toxicity tests of different experiment conditions (light/dark, culture medium, and solvent) were conducted on with BaP as the toxicant of concern. Based on the experiments above, molecular dynamics (MD) simulations were employed to investigate the mechanisms of action. According to our results, the significant influence of light exposure on the acute toxicity test of BaP ( < 0.05) on was recorded. On the basis of the MD simulations, it was possible that BaP may not affect the normal operation of Superoxide Dismutase and Catalase directly, and it could be quickly transferred from the body through Glutathione S-transferase and Cytochromes P450. Therefore, when exposed to light, the oxidative stress process intensifies, causing damage to . Apparently, the ecotoxicity tests based on inhibition for cannot adequately reflect the toxic effects of BaP.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11510787PMC
http://dx.doi.org/10.3390/toxics12100714DOI Listing

Publication Analysis

Top Keywords

acute toxicity
16
extreme variation
8
toxicity test
8
toxicity tests
8
bap
5
variation benzo[a]pyrene
4
acute
4
benzo[a]pyrene acute
4
toxicity
4
test enormous
4

Similar Publications

Prognostic models for radiation-induced complications after radiotherapy in head and neck cancer patients.

Cochrane Database Syst Rev

September 2025

Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands.

Background: Radiotherapy is the mainstay of treatment for head and neck cancer (HNC) but may induce various side effects on surrounding normal tissues. To reach an optimal balance between tumour control and toxicity prevention, normal tissue complication probability (NTCP) models have been reported to predict the risk of radiation-induced side effects in patients with HNC. However, the quality of study design, conduct, and analysis (i.

View Article and Find Full Text PDF

Background: Tacrolimus is a commonly used immunosuppressant with well-defined side effects, including hypertriglyceridemia and hyperglycaemia. However, acute pancreatitis is still not widely recognized as an adverse event related to tacrolimus.

Case Presentation: A 60-year-old male was admitted to the intensive care unit with symptoms and signs of acute pancreatitis.

View Article and Find Full Text PDF

Case Report: Effective methotrexate removal by combined hemodialysis and polymeric resin hemoadsorption.

Front Nephrol

August 2025

Department of Nephrology, Instituto Português de Oncologia do Porto Francisco Gentil, Porto, Portugal.

Background: High-dose methotrexate (HDMTX) is central to treating primary central nervous system lymphoma but carries a risk of acute kidney injury (AKI), which can delay methotrexate (MTX) clearance and increase toxicity. Glucarpidase is the treatment of choice for MTX toxicity, but limited access in many countries may necessitate alternatives. We present the first reported adult case of combined high-flux hemodialysis (HFHD) and HA230 hemoadsorption for MTX clearance.

View Article and Find Full Text PDF

Methemoglobinemia is an uncommon yet potentially life-threatening condition that results from the oxidation of iron from the ferrous (Fe²⁺) to the ferric (Fe³⁺) state, rendering hemoglobin unable to effectively transport oxygen. This translates into a state of functional hypoxia despite adequate arterial oxygen tension. Among the various causes of acquired methemoglobinemia, recreational inhalation of alkyl nitrites, widely known as "poppers," is a notable but underrecognized trigger.

View Article and Find Full Text PDF

The Impact of Cytoreduction on Blinatumomab Outcomes for Relapsed or Refractory B-ALL With High Disease Burden.

Am J Hematol

September 2025

Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, California, USA.

Blinatumomab is approved for the treatment of relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). Studies have correlated pre-blinatumomab high disease burden (HDB) [> 50% bone marrow blasts (BMB)] with lower response rates and increased risk for toxicities, including cytokine release syndrome (CRS) and neurotoxicity (NT). While the administration of pre-blinatumomab cytoreductive therapy is an appealing approach, larger studies validating the beneficial effect of this strategy in patients with HDB are lacking.

View Article and Find Full Text PDF